Table 4.
Risk factors associated with survival after the onset of thromboembolism and/or DIC
| Characteristics | n | Median (days) | Univariate analysis
|
Multivariate analysis
|
|
|---|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | |||
| Age (years) | |||||
| Older (≥75 years) | 6 | 16 | 0.5159 | 0.97 (0.31–3.03) | 0.9627 |
| Younger (<75 years) | 34 | 38 | |||
| EGFR mutation or ALK fusion | |||||
| No | 32 | 28 | 0.0469 | 3.21 (1.16–8.92) | 0.0249 |
| Yes | 8 | 199 | |||
| ILD | |||||
| Yes | 10 | 38 | 0.3639 | 0.73 (0.23–2.33) | 0.5903 |
| No | 30 | 38 | |||
| Histology | |||||
| Small | 6 | 28 | |||
| Adenocarcinoma | 27 | 118 | 0.0202 | 0.42 (0.13–1.33) | 0.1395 |
| Squamous | 12 | 12 | |||
| TE/DIC | |||||
| TE | 25 | 223 | |||
| DIC | 21 | 13 | <0.0001 | 8.45 (2.87–24.89) | 0.0001 |
| Chemotherapy or molecular-targeted therapy, response | |||||
| No | 14 | 8 | <0.0001 | 9.69 (2.68–35.11) | 0.0005 |
| Yes, PD | 12 | 28 | |||
| Yes, SD or PR | 14 | 365 | |||
| Anticoagulation therapy | |||||
| No | 8 | 8 | 0.0027 | 2.45 (0.85–7.06) | 0.0977 |
| Yes | 32 | 83 | |||
Abbreviations: ALK, anaplastic lymphoma kinase; DIC, disseminated intravascular coagulation; EGFR, epidermal growth factor receptor; ILD, interstitial lung disease; PD, progressive disease; PR, partial response; SD, stable disease; TE, thromboembolism.